Signaturefd LLC Buys 346 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Signaturefd LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 13.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,894 shares of the medical research company’s stock after purchasing an additional 346 shares during the period. Signaturefd LLC’s holdings in IQVIA were worth $569,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. GSA Capital Partners LLP bought a new stake in IQVIA during the third quarter worth about $230,000. Empowered Funds LLC grew its position in IQVIA by 33.9% during the 3rd quarter. Empowered Funds LLC now owns 3,437 shares of the medical research company’s stock worth $814,000 after acquiring an additional 871 shares during the last quarter. Thrivent Financial for Lutherans increased its holdings in IQVIA by 20.6% during the 3rd quarter. Thrivent Financial for Lutherans now owns 43,177 shares of the medical research company’s stock valued at $10,231,000 after purchasing an additional 7,369 shares in the last quarter. Pathstone Holdings LLC raised its position in IQVIA by 4.8% in the 3rd quarter. Pathstone Holdings LLC now owns 14,492 shares of the medical research company’s stock valued at $3,434,000 after purchasing an additional 667 shares during the last quarter. Finally, Caprock Group LLC boosted its stake in IQVIA by 11.7% in the third quarter. Caprock Group LLC now owns 3,003 shares of the medical research company’s stock worth $712,000 after purchasing an additional 315 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 0.9 %

Shares of NYSE IQV opened at $186.80 on Thursday. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $256.29. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a market cap of $32.93 billion, a P/E ratio of 24.91, a P/E/G ratio of 1.99 and a beta of 1.50. The firm has a 50 day moving average price of $195.71 and a 200 day moving average price of $209.36.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IQV. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Barclays reduced their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Citigroup lowered their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Stifel Nicolaus reduced their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, JPMorgan Chase & Co. dropped their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.